•
Mar 31, 2022

PMV Pharma Q1 2022 Earnings Report

Reported financial results for the first quarter ended March 31, 2022.

Key Takeaways

PMV Pharmaceuticals reported a net loss of $18.4 million for the quarter ended March 31, 2022. As of March 31, 2022, the company had $294.8 million in cash, cash equivalents, and marketable securities.

PMV Pharma had $294.8 million in cash, cash equivalents, and marketable securities as of March 31, 2022.

Net loss for the quarter ended March 31, 2022 was $18.4 million.

Research and development expenses were $11.8 million for the quarter ended March 31, 2022.

General and administrative expenses were $6.8 million for the quarter ended March 31, 2022.

EPS
-$0.41
Previous year: -$0.26
+57.7%
Cash and Equivalents
$116M
Previous year: $209M
-44.5%
Free Cash Flow
-$18.8M
Total Assets
$315M
Previous year: $354M
-11.1%

PMV Pharma

PMV Pharma